Protein Kinase C-β as a Therapeutic Target in Breast Cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 9, 2006, Pages 15-18

  Sledge Jr , George W ^a   Gökmen Polar, Yesim ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ENZASTAURIN; GEMCITABINE; LY 379196; PACLITAXEL; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH;

BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE C; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745200542     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.03.019     Document Type: Article

References (43)

1. Fields A.P., and Gustafson W.C. Protein kinase C in disease. In: Newton A.C. (Ed). Methods in Molecular Biology, vol 233. Protein kinase C protocols (2003), Humana Press Inc, Totowa, NJ 519-537
2. Goekjian P.G., and Jirousek M.R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Invest Drugs 10 (2001) 2117-2140
3. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4 (2004) 125-146
4. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334 (1988) 661-665
5. Hug H., and Sarre T.F. Protein kinase C isoenzymes. Divergence in signal transduction?. Biochem J 291 (1993) 329-343
6. Hocevar B.A., Morrow D.M., Tykocinski M.L., et al. Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation. J Cell Sci 101 (1992) 671-679
7. Murray N.R., Baumgardner G.P., Burns D.J., et al. Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that βII protein kinase C is required for proliferation. J Biol Chem 268 (1993) 15847-15853
8. Ono Y., Kikkawa U., Ogita K., et al. Expression and properties of two types of protein kinase C. Alternative splicing from a single gene. Science 236 (1987) 1116-1120
9. Murray N.R., Davidson L.A., Chapkin R.S., et al. Overexpression of protein kinase C βII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 145 (1999) 699-711
10. Black J.D. Protein kinase C isozymes in colon carcinogenesis. Guilt by omission. Gastroenterology 120 (2001) 1868-1872
11. Gökmen-Polar Y., Murray N.R., Velasco M.A., et al. Elevated protein kinase C beta II is an early promotive event in colon carcinogenesis. Cancer Res 61 (2001) 1375-1381
12. Zhang J., Anastasiadis P.Z., Liu Y., et al. Protein kinase C (PKC) βII induces cell invasion through a Ras/Mek-, PKCiota/Rac 1-dependent signaling pathway. J Biol Chem 279 (2004) 22118-22123
13. Suga K., Sugimoto I., Ito H., et al. Down-regulation of protein kinase C alpha detected in human colorectal cancer. Biochem Mol Biol Int 44 (1998) 523-528
14. Davidson L.A., Brown R.E., Chang W.C., et al. Morphodensitometric analysis of protein kinase C beta (II) expression in rat colon. Modulation by diet and relation to in situ cell proliferation and apoptosis. Carcinogenesis 21 (2000) 1513-1519
15. Klein I.K., Ritland S.R., Burgart L.J., et al. Adenoma-specific alterations of protein kinase C expression in Apc(MIN) mice. Cancer Res 60 (2000) 2077-2080
16. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
17. da Rocha A.B., Mans D.R., Regner A., et al. Targeting protein kinase C. New therapeutic opportunities against high-grade malignant gliomas?. Oncologist 7 (2002) 17-33
18. Su T.T., Guo B., Kawakami Y., et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 3 (2002) 780-786
19. O'Brian C.A., Vogel V.G., Singletary S.E., et al. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49 (1989) 3215-3217
20. Gordge P.C., Hulme M.J., Clegg R.A., et al. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer 32A (1996) 2120-2126
21. 2+-dependent protein kinase of human mammary carcinoma cells. Inverse relationship to estrogen receptors. Int J Cancer 40 (1987) 344-348
22. Lee S.A., Karaszkiewicz J.W., and Anderson W.B. Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res 52 (1992) 3750-3759
23. Kiley S.C., Clark K.J., Duddy S.K., et al. Increased protein kinase Cδ in mammary tumor cells. relationship to transformation and metastasic progression. Oncogene 18 (1999) 6748-6757
24. Kiley S.C., Clark K.J., Goodnough M., et al. Protein Kinase Cδ involvement in mammary tumor cell metastasis. Cancer Res 59 (1999) 3230-3238
25. Lahn M., Köhler G., Sundell K., et al. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 67 (2004) 1-10
26. Ways D.K., Kukoly C.A., deVente J., et al. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95 (1995) 1906-1915
27. Morse-Gaudio M., Connolly J.M., and Rose D.P. Protein kinase C and its isoforms in human breast cancer cells. Relationship to the invasive phenotype. Int J Oncol 12 (1998) 1349-1354
28. Manni A., Buckwalter E., Etindi R., et al. Induction of a less aggressive breast cancer phenotype by protein kinase C-α and β-overexpression. Cell Growth Differ 7 (1996) 1187-1198
29. Nabha S.M., Glaros S., Hong M., et al. Upregulation of PKCδ contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24 (2005) 3166-3176
30. Chalfant C.E., Mishak H., Watson J.E., et al. Regulation of alternative splicing of protein kinase C beta by insulin. J Biol Chem 270 (1995) 13326-13332
31. Xia P., Aiello L.P., Ishii H., et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98 (1996) 2018-2026
32. Takahashi T., Ueno H., and Shibuya M. VEGF activates protein kinase C-dependent, but Ras independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18 (1999) 2221-2230
33. Zachary I. VEGF signaling. integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 6 (2003) 1171-1177
34. Yoshiji H., Kuriyama S., Ways D.K., et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59 (1999) 4413-4418
35. Miller K.D., Wang M., Gralow J.D., et al. E2100. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (2004), Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL May 13-17
36. Graff J.R., McNulty A.M., Hanna K.R., et al. The protein kinase cb-selective inhibitor, enzastaurin (LY317615.HCL), supressess signaling through the Akt pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (2005) 7462-7469
37. Teicher B.A., Alvarez E., Menon K., et al. Antiangiogenic effects of a protein kinase Cβ-selective small molecule. Cancer Chemother Pharmacol 49 (2002) 69-77
38. Keyes K.A., Mann L., Sherman M., et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53 (2004) 133-140
39. Teicher B.A., Menon K., Alvarez E., et al. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 20 (2002) 241-251
40. Herbst R.S., Thornton D.E., Kies M.S., et al. Phase 1 study of LY317615, a protein kinase Cb inhibitor. Proc Am Soc Clin Oncol 21 (2002) 326 abstr
41. Rademaker-Lakhai J.M. Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin. Proc Am Soc Clin Oncol 24 (2004) 3129 abstr
42. Fine H.A., Royce K.M., Draper D., et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc Am Soc Clin Oncol 23 (2005) 1504 abstr
43. Robertson M., Kahl B., Vose J., et al. A phase II study of enzastaurin, a protein kinase C-β (PKCβ) inhibitor, in the treatment of relapsed diffuse large B-cell lymphoma (DLBCL). Blood 106 (2005) 934 abstr